Project Grant HT94252310764

This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $456,103 in funding to The Feinstein Institutes for Medical Research to develop integrated risk models for endometrial cancer. The project aims to enhance early detection of endometrial cancer by determining the burden of rare genetic risk factors and creating predictive models that integrate genetic and non-genetic factors such as BMI, diabetes, and PCOS. The research will...

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

Federal Grant Award Summary Xgenomes Corp. received a $399,816 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning September 1, 2025, and concluding August 31, 2026. The company will develop a novel circulating tumor DNA (ctDNA) analysis platform that directly measures both genetic mutations and methylation changes with accuracy exceeding current next-generation sequencing methods by over 100-fold. The technology...

The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...

This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...

Federal Grant Award Summary: Advancing Hormone Therapy for Endometrial Cancer The National Cancer Institute (NCI) awarded the University of New Mexico Health Sciences Center a $2.8 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 8, 2025, with a project completion date of July 31, 2030. This multi-institutional Program Project (P01) grant seeks to improve clinical outcomes for patients with uterine endometrial cancer and atypical endometrial...

GRANT SUMMARY The National Cancer Institute awarded Weill Medical College of Cornell University a $607,849 Project Grant on August 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a five-year research initiative examining mechanisms of genetic and non-genetic resistance to KRAS (Kirsten Rat Sarcoma) inhibition in lung adenocarcinoma and colorectal cancer. The research aims to identify why patients develop resistance to newly emerged mutant-selective and pan-KRAS...

Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...